[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 20, Issue 1 (1-2022) ::
Int J Radiat Res 2022, 20(1): 37-41 Back to browse issues page
Long-term outcome of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate and high risk prostate cancer
H.J. Kim , J.S. Lee, W.C. Kim
Department of Radiation Oncology, Inha University Hospital, Inha University of Medicine, Inchon, Korea , cancerovercome@gmail.com
Abstract:   (799 Views)
Background: We report our long-term outcomes with Cyberknife to deliver hypofractionated SBRT boost combined with EBRT to patients with intermediate to high risk prostate cancer. Materials And Methods: From March 2008 to July 2014, 42 patients with newly diagnosed, intermediate (73.8%, 31) and high risk (26.2%, 11) localized prostate cancer were treated with EBRT and SBRT boost. The whole pelvis dose was 45 Gy (25 fractions of 1.8 Gy) and the SBRT boost dose was 21 Gy (3 fractions of 7 Gy). Results: With a median follow-up duration of 84.2 months (range, 20-139.6), the median PSA decline rates were -0.605, -0.229, -0.166 and -0.094 ng/mL/month, respectively, for durations of 1, 2, 3 and 4 years after radiotherapy and has remained near plateau. Four BCFs were observed only in high risk group. The actuarial 8 year BCF free survival and overall survival were 90.3 % and 83.7 %, respectively. BCF-free survival at 8 years were 100 % and 77.8 % for intermediate and high risk group, respectively (p=0.014). No grade 3 or 4 acute and late genitourinary (GU) and gastrointestinal (GI) toxicities were observed. Acute grade 2 GU toxicities were seen in 23.8 % (n = 10) and acute grade 2 GI toxicities in 21.4 % (n = 9). Late grade 2 GU toxicities were observed in 11.9 % (n = 5) and grade 2 GI toxicities in 14.2 % (n = 6). Conclusions: We demonstrated that SBRT boost after EBRT in intermediate- and high-risk prostate cancer had favorable outcomes with tolerable toxicities.
 
Keywords: Cyberknife, prostate cancer, PSA, radiotherapy, stereotactic body radiotherapy.
Full-Text [PDF 1533 kb]   (567 Downloads)    
Type of Study: Original Research | Subject: Radiobiology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kim H, Lee J, Kim W. Long-term outcome of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate and high risk prostate cancer. Int J Radiat Res. 2022; 20 (1) :37-41
URL: http://ijrr.com/article-1-4065-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 20, Issue 1 (1-2022) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 32 queries by YEKTAWEB 4410